Date: 2012-05-22
Type of information:
phase:
Announcement: results
Company: Prometheus Laboratories (USA - part of Nestlé Health Science - Switzerland)
Product: prediction test
Action mechanism:
Disease: inflammatory bowel disease
Therapeutic area: Inflammatory diseases
Country:
Trial details:
Latest
news: Prometheus Laboratories, a company acquired by Nestlé Health Science, has presented new research that confirms the effectiveness of its new diagnostic test designed to improve treatment management for patients with inflammatory bowel disease (IBD). The test is designed to predict inflammatory bowel disease activity and measure the impact of infliximab, a drug used by patients to help prevent inflammation.
Over time, some of them become less responsive to the drug so it is vital for medical practitioners to be able to diagnose this early on so a different course of treatment can be found. The test should help ensure patients with chronic inflammatory bowel disorders can be treated effectively. These include ulcerative colitis and Crohn\'s disease which typically cause abdominal pain, fever and diarrhoea. The data, reported by the company at this year’s Digestive Disease Week event in San Diego, in the United States, provides evidence of the effectiveness of the company’s new monitoring test which will be launched later this year.
Nestlé Health Science acquired Prometheus Laboratories mid 2011 (See http://biopharmanalyses.fr/merges-and-acquisitions/?pageid=4)
